Overview

Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Status:
Not yet recruiting
Trial end date:
2024-02-14
Target enrollment:
Participant gender:
Summary
To clarify the uric acid-lowering efficacy of orlistat in overweight/obese patients with hyperuricemia, and to evaluate the safety of orlistat treatment
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai 10th People's Hospital
Treatments:
Orlistat